Cargando…
Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
BACKGROUND & OBJECTIVE: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Society of Pathology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293598/ https://www.ncbi.nlm.nih.gov/pubmed/37383162 http://dx.doi.org/10.30699/IJP.2023.561917.2969 |
_version_ | 1785063022898708480 |
---|---|
author | Ahadi, Mahsa Moradi, Afshin Rabiee, Elham Pourmotahari, Fatemeh |
author_facet | Ahadi, Mahsa Moradi, Afshin Rabiee, Elham Pourmotahari, Fatemeh |
author_sort | Ahadi, Mahsa |
collection | PubMed |
description | BACKGROUND & OBJECTIVE: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers. METHODS: This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed. RESULTS: The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics. CONCLUSION: GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable. |
format | Online Article Text |
id | pubmed-10293598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Iranian Society of Pathology |
record_format | MEDLINE/PubMed |
spelling | pubmed-102935982023-06-28 Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers Ahadi, Mahsa Moradi, Afshin Rabiee, Elham Pourmotahari, Fatemeh Iran J Pathol Original Article BACKGROUND & OBJECTIVE: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers. METHODS: This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed. RESULTS: The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics. CONCLUSION: GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable. Iranian Society of Pathology 2023 2023-03-23 /pmc/articles/PMC10293598/ /pubmed/37383162 http://dx.doi.org/10.30699/IJP.2023.561917.2969 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License (https://creativecommons.org/licenses/by/4.0/) which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially. |
spellingShingle | Original Article Ahadi, Mahsa Moradi, Afshin Rabiee, Elham Pourmotahari, Fatemeh Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers |
title | Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers |
title_full | Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers |
title_fullStr | Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers |
title_full_unstemmed | Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers |
title_short | Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers |
title_sort | evaluation of gata3 and gcdfp15 expression in triple negative breast cancers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293598/ https://www.ncbi.nlm.nih.gov/pubmed/37383162 http://dx.doi.org/10.30699/IJP.2023.561917.2969 |
work_keys_str_mv | AT ahadimahsa evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers AT moradiafshin evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers AT rabieeelham evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers AT pourmotaharifatemeh evaluationofgata3andgcdfp15expressionintriplenegativebreastcancers |